AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Spexis AG

Report Publication Announcement Oct 6, 2023

957_iss_2023-10-06_91b047c6-d346-44f8-a299-983673956861.html

Report Publication Announcement

Open in Viewer

Opens in native device viewer

Spexis AG / Key word(s): Statement

Spexis to host business update conference call on October 9, 2023

06.10.2023 / 07:30 CET/CEST


Spexis to host business update conference call on October 9, 2023

Allschwil, Switzerland, October 6, 2023

Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on macrocycle therapeutics for rare diseases and oncology, announced today that it will host a business update conference call on October 9, 2023, at 8.30am EDT.

Jeffrey D. Wager, M.D. (CEO & Chairman) will provide strategic business and financial updates. To access the conference call please use the following details:

France: +33 0805102207

Germany: +49 0800-6647650

Italy: +39 800897553

Switzerland +41 0800-002063

United Kingdom +44 08082389064

United States +1 877-317-6789

International Toll Free +1 412-317-6789

Event Title: Spexis AG – Business Update Conference Call

The conference call will also be available via webcast:  https://event.choruscall.com/mediaframe/webcast.html?webcastid=6s6eCE7g

After the call, a replay of the webcast will be available via the above link.

About Spexis

Spexis (SIX: SPEX) is a clinical-stage biopharmaceutical company based in Allschwil, Switzerland, focused on macrocycle therapeutics for rare diseases and oncology. For further information please visit:  www.spexisbio.com .

For further information please contact:

For Investors:  

Hernan Levett

Chief Financial Officer

Spexis AG.

+41 61 567 16 00

[email protected]

Or

Stephen Jasper

Managing Director

Gilmartin Group

[email protected]

For Media:  

Dr. Stephan Feldhaus

Feldhaus & Partner

+41 79 865 92 56

[email protected]


End of Media Release


Language: English
Company: Spexis AG
Hegenheimermattweg 125
4123 Allschwil
Switzerland
Phone: +41 61 567 1600
Fax: +41 61 567 1601
E-mail: [email protected]
Internet: www.spexisbio.com
ISIN: CH0106213793
Valor: SPEX
Listed: SIX Swiss Exchange
EQS News ID: 1742821
End of News EQS News Service

1742821  06.10.2023 CET/CEST

Talk to a Data Expert

Have a question? We'll get back to you promptly.